Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QM1114-DP for Lateral Canthal and Glabellar Lines
NCT05148000Phase 3Completed
- Sponsor
- Galderma
- Start
- Jan 2023
- Primary completion
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of relabotulinumtoxinA in glabellar rhytides, lateral canthal rhytides, sponsored by Galderma. Started Jan 2023; status: completed.
02
Drugs
relabotulinumtoxinA
03
Conditions
glabellar rhytideslateral canthal rhytides
Beyond the preview
Go deeper on NCT05148000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05148000.